Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated

NCT04582344 is registered in ClinicalTrials.gov with Health Institutes of Turkey as lead sponsor.

NCT NCT04582344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04582344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Lead sponsor
Health Institutes of Turkey
Phase
Phase 3
Overall status
Completed
Start date
September 14, 2020
Completion date
July 27, 2022
Enrollment
10,214 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19